Lodé, L., Ménard, A., Flet, L., Richebourg, S., Loirat, M., Eveillard, M., . . . Peterlin, P. (2018). Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide. Haematologica.
Citación estilo ChicagoLodé, Laurence, et al. "Emergence and Evolution of TP53 Mutations Are Key Features of Disease Progression in Myelodysplastic Patients With Lower-risk Del(5q) Treated With Lenalidomide." Haematologica 2018.
Cita MLALodé, Laurence, et al. "Emergence and Evolution of TP53 Mutations Are Key Features of Disease Progression in Myelodysplastic Patients With Lower-risk Del(5q) Treated With Lenalidomide." Haematologica 2018.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.